Preliminary Report - ID Mapping
Differences
This shows you the differences between two versions of the page.
Both sides previous revision Previous revision Next revision | Previous revision Next revision Both sides next revision | ||
covid:unpublished [2020/06/02 13:55] biogridadmin |
covid:unpublished [2020/07/02 16:14] biogridadmin |
||
---|---|---|---|
Line 9: | Line 9: | ||
| **888800000001** | **[[https://doi.org/10.1101/2020.03.22.002386|10.1101/2020.03.22.002386]]** | Gordon DE (2020) | **[[https://thebiogrid.org/220839/publication|A SARS-CoV-2-Human Protein-Protein Interaction Map Reveals Drug Targets and Potential Drug-Repurposing]]** | | | **888800000001** | **[[https://doi.org/10.1101/2020.03.22.002386|10.1101/2020.03.22.002386]]** | Gordon DE (2020) | **[[https://thebiogrid.org/220839/publication|A SARS-CoV-2-Human Protein-Protein Interaction Map Reveals Drug Targets and Potential Drug-Repurposing]]** | | ||
| **888800000002** | **[[https://doi.org/10.1101/2020.03.29.20041962|10.1101/2020.03.29.20041962]]** | Gao T (2020) | **[[https://thebiogrid.org/221112/publication|Highly pathogenic coronavirus N protein aggravates lung injury by MASP-2-mediated complement over-activation]]** | | | **888800000002** | **[[https://doi.org/10.1101/2020.03.29.20041962|10.1101/2020.03.29.20041962]]** | Gao T (2020) | **[[https://thebiogrid.org/221112/publication|Highly pathogenic coronavirus N protein aggravates lung injury by MASP-2-mediated complement over-activation]]** | | ||
- | | **888800000003** | **[[https://doi.org/10.1101/2020.02.16.951723|10.1101/2020.02.16.951723]]** | Xie L (2020) | **[[https://thebiogrid.org/221178/publication|SARS-CoV-2 and SARS-CoV Spike-RBD Structure and Receptor Binding Comparison and Potential Implications on Neutralizing Antibody and Vaccine Development]]** | | + | | **888800000003** | **[[https://doi.org/10.1101/2020.02.16.951723|10.1101/2020.02.16.951723]]** | Sun C (2020) | **[[https://thebiogrid.org/221178/publication|SARS-CoV-2 and SARS-CoV Spike-RBD Structure and Receptor Binding Comparison and Potential Implications on Neutralizing Antibody and Vaccine Development]]** | |
| **888800000004** | **[[https://doi.org/10.1101/2020.03.16.994236|10.1101/2020.03.16.994236]]** | Procko E (2020) | **[[https://thebiogrid.org/221182/publication|The sequence of human ACE2 is suboptimal for binding the S spike protein of SARS coronavirus 2]]** | | | **888800000004** | **[[https://doi.org/10.1101/2020.03.16.994236|10.1101/2020.03.16.994236]]** | Procko E (2020) | **[[https://thebiogrid.org/221182/publication|The sequence of human ACE2 is suboptimal for binding the S spike protein of SARS coronavirus 2]]** | | ||
| **888800000005** | **[[https://doi.org/10.1101/2020.03.14.988345|10.1101/2020.03.14.988345]]** | Wang K (2020) | **[[https://thebiogrid.org/221183/publication|SARS-CoV-2 invades host cells via a novel route: CD147-spike protein]]** | | | **888800000005** | **[[https://doi.org/10.1101/2020.03.14.988345|10.1101/2020.03.14.988345]]** | Wang K (2020) | **[[https://thebiogrid.org/221183/publication|SARS-CoV-2 invades host cells via a novel route: CD147-spike protein]]** | | ||
Line 19: | Line 19: | ||
| **888800000012** | **[[https://doi.org/10.1101/2020.03.31.019216|10.1101/2020.03.31.019216]]** | Liang Q (2020) | **[[https://thebiogrid.org/221199/publication|Virus-host interactome and proteomic survey of PMBCs from COVID-19 patients reveal potential virulence factors influencing SARS-CoV-2 pathogenesis]]** | | | **888800000012** | **[[https://doi.org/10.1101/2020.03.31.019216|10.1101/2020.03.31.019216]]** | Liang Q (2020) | **[[https://thebiogrid.org/221199/publication|Virus-host interactome and proteomic survey of PMBCs from COVID-19 patients reveal potential virulence factors influencing SARS-CoV-2 pathogenesis]]** | | ||
| **888800000013** | **[[https://doi.org/10.1101/2020.04.15.042085|10.1101/2020.04.15.042085]]** | Bestle D (2020) | **[[https://thebiogrid.org/221402/publication|TMPRSS2 and furin are both essential for proteolytic activation and spread of SARS-CoV-2 in human airway epithelial cells and provide promising drug targets]]** | | | **888800000013** | **[[https://doi.org/10.1101/2020.04.15.042085|10.1101/2020.04.15.042085]]** | Bestle D (2020) | **[[https://thebiogrid.org/221402/publication|TMPRSS2 and furin are both essential for proteolytic activation and spread of SARS-CoV-2 in human airway epithelial cells and provide promising drug targets]]** | | ||
- | | **888800000014** | **[[https://doi.org/10.1101/2020.04.09.033233|10.1101/2020.04.09.033233]]** | Jin Z (2020) | **[[https://thebiogrid.org/221403/publication|Structural basis for the inhibition of COVID-19 virus main protease by carmofur, an antineoplastic drug]]** | | ||
- | | **888800000015** | **[[https://doi.org/10.1101/2020.04.08.032763|10.1101/2020.04.08.032763]]** | Yin W (2020) | **[[https://thebiogrid.org/221404/publication|Structural Basis for the Inhibition of the RNA-Dependent RNA Polymerase from SARS-CoV-2 by Remdesivir]]** | | ||
| **888800000016** | **[[https://doi.org/10.1101/2020.04.14.042010|10.1101/2020.04.14.042010]]** | Chi X (2020) | **[[https://thebiogrid.org/221405/publication|Humanized Single Domain Antibodies Neutralize SARS-CoV-2 by Targeting Spike Receptor Binding Domain]]** | | | **888800000016** | **[[https://doi.org/10.1101/2020.04.14.042010|10.1101/2020.04.14.042010]]** | Chi X (2020) | **[[https://thebiogrid.org/221405/publication|Humanized Single Domain Antibodies Neutralize SARS-CoV-2 by Targeting Spike Receptor Binding Domain]]** | | ||
| **888800000017** | **[[https://doi.org/10.1101/2020.04.06.20055475|10.1101/2020.04.06.20055475]]** | Ye L (2020) | **[[https://thebiogrid.org/221565/publication|Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor]]** | | | **888800000017** | **[[https://doi.org/10.1101/2020.04.06.20055475|10.1101/2020.04.06.20055475]]** | Ye L (2020) | **[[https://thebiogrid.org/221565/publication|Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor]]** | |